Free Trial

Rein Therapeutics (RNTX) Institutional Ownership

Rein Therapeutics logo
$1.13 -0.03 (-2.93%)
As of 09:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Institutional Ownership Changes (13F Filings) for Rein Therapeutics (NASDAQ:RNTX)

Current
Institutional Ownership
Percentage
90.89%
Number of
Institutional Buyers
(last 12 months)
23
Total
Institutional Inflows
(last 12 months)
$11.86M
Number of
Institutional Sellers
(last 12 months)
2
Total
Institutional Outflows
(last 12 months)
$168.01K
Get RNTX Insider Trade Alerts

Want to know when executives and insiders are buying or selling Rein Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Chart & View Institutional Buying and Selling Data

RNTX Institutional Buying and Selling by Quarter

Rein Therapeutics Major Shareholders & Ownership History

Reporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/5/2026 Sigma Planning Corp348,677$453K0.0%+41.0%1.243%
5/4/2026 Chicago Partners Investment Group LLC41,048$53K0.0%+32.2%0.146%
2/13/2026Prosight Management LP442,600$513K0.1%-22.1%1.684%
2/13/2026State Street Corp75,904$88K0.0%+374.3%0.289%
2/13/2026Voss Capital LP4,243,969$4.92M0.2%+59.2%16.143%
2/13/2026 Gagnon Securities LLC240,220$279K0.1%+5.0%0.914%
2/12/2026 Jane Street Group LLC61,960$72K0.0%N/A0.236%
2/12/2026HRT Financial LP33,237$38K0.0%N/A0.126%
2/10/2026 Rock Creek Group LP100,000$116K0.0%N/A0.380%
2/9/2026Geode Capital Management LLC284,555$330K0.0%+15.1%1.083%
2/9/2026 Texas Capital Bank Wealth Management Services Inc262,125$304K0.0%+901.6%0.997%
1/30/2026ABS Direct Equity Fund LLC125,000$145K0.2%N/A0.475%
11/20/2025Voss Capital LP2,666,532$3.05M0.1%+86.0%10.143%
11/17/2025Susquehanna International Group LLP30,860$35K0.0%N/A0.132%
11/17/2025Citadel Advisors LLC28,201$32K0.0%-41.2%0.121%
11/14/2025Prosight Management LP567,898$650K0.2%+32.7%2.436%
11/7/2025Vanguard Group Inc.1,168,407$1.34M0.0%+32.2%5.014%
11/3/2025 Gagnon Securities LLC228,692$262K0.1%+218.8%0.981%
10/16/2025 Gleason Group Inc.22,389$26K0.0%N/A0.096%
8/14/2025Cable Car Capital LP420,000$588K0.2%N/A1.822%
8/14/2025Voss Capital LP1,433,686$2.01M0.1%N/A6.221%
8/13/2025 Northwestern Mutual Wealth Management Co.48,662$68K0.0%N/A0.211%
8/12/2025BIOS Capital Management LP1,690,751$2.37M3.3%N/A7.335%
8/12/2025 Meridian Wealth Advisors LLC28,486$40K0.0%N/A0.124%
8/11/2025Senvest Management LLC230,895$323K0.0%N/A1.002%
8/8/2025Geode Capital Management LLC245,455$344K0.0%N/A1.065%
8/5/2025 Sigma Planning Corp276,777$387K0.0%N/A1.201%
7/31/2025 University of Texas Texas AM Investment Management Co.511,610$716K0.1%N/A2.310%
7/30/2025 Exencial Wealth Advisors LLC30,528$43K0.0%N/A0.138%
7/29/2025 Chicago Partners Investment Group LLC41,242$64K0.0%N/A0.186%
7/24/2025 Blair William & Co. IL23,622$33K0.0%N/A0.107%


RNTX Institutional Ownership - Frequently Asked Questions

During the previous two years, 24 institutional investors and hedge funds held shares of Rein Therapeutics. The most heavily invested institutionals were Voss Capital LP ($4.92M), BIOS Capital Management LP ($2.37M), Vanguard Group Inc. ($1.34M), University of Texas Texas AM Investment Management Co. ($716K), Cable Car Capital LP ($588K), Prosight Management LP ($513K), and Sigma Planning Corp ($453K).Learn more on Rein Therapeutics' institutional investors.

90.89% of Rein Therapeutics' stock is owned by institutional investors. Learn more on RNTX's institutional investor holdings.

Of the 23 institutional investors that purchased Rein Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Voss Capital LP ($4.24M), BIOS Capital Management LP ($1.69M), University of Texas Texas AM Investment Management Co. ($511.61K), Cable Car Capital LP ($420K), Sigma Planning Corp ($378.18K), Vanguard Group Inc. ($284.30K), and Geode Capital Management LLC ($282.70K).

Institutional investors have bought a total of 9,202,695 shares in the last 24 months. This purchase volume represents approximately $11.86M in transactions.

The following institutional investors have sold Rein Therapeutics stock in the last 24 months: Prosight Management LP ($125.30K), and Citadel Advisors LLC ($19.79K).

Institutional investors have sold a total of 145,091 shares in the last 24 months. This volume of shares sold represents approximately $168.01K in transactions.



This page (NASDAQ:RNTX) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners